Use of psychedelic substances is increasing across unregulated, state-regulated, research, ceremonial/religious, and medical settings in the United States. Concurrently, a growing body of clinical research signals the potential for therapeutic applications for specific psychedelics in the treatment of depression, post-traumatic stress disorder, substance use disorders, and other health...
There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food...